2016年ACR-EULAR肌炎应答标准在成人皮肌炎/多发性肌炎治疗试验及共识病例中的表现
研究评估2016年ACR-EULAR肌炎应答标准(MRC)在成人皮肌炎/多发性肌炎中的表现,数据来自利妥昔单抗(n=147)、依那西普(n=14)、阿巴西普(n=19)试验及共识患者病例(n=232)。412例成人中无、轻微、中度、重大改善分别占37%、24%、25%、14%;至少轻微改善者中95%有肌肉相关指标改善,84%有患者报告结局改善。结论认为MRC在多项研究中表现一致,支持其作为未来肌炎治疗试验的疗效终点。
要点
- 412例成人皮肌炎/多发性肌炎中,无、轻微、中度、重大MRC改善分别占37%、24%、25%、14%。
- 至少轻微改善者中95%有肌肉相关指标改善,84%有患者报告结局改善。
- 轻微改善者中位有1项核心指标恶化,中度-重大改善者多数无核心指标恶化。
核心结论
- ACR-EULAR MRC在多项研究中表现一致,进一步支持其作为未来肌炎治疗试验的疗效终点。
研究设计与样本
- 评估成人皮肌炎/多发性肌炎患者数据,包括利妥昔单抗试验(n=147)、依那西普试验(n=14)、阿巴西普试验(n=19)及共识患者病例(n=232)。
- 采用总改善评分(TIS)、改善与恶化的核心指标数量、有无肌肉相关指标的改善频率及患者报告结局指标的贡献,按MRC分类评估。
- 进行回归分析以评估每个核心指标对MRC的贡献。
主要发现
- 412例成人皮肌炎/多发性肌炎中,无、轻微、中度、重大MRC改善分别占37%、24%、25%、14%。
- 改善的核心指标数量及所有核心指标的绝对百分比变化随改善等级增加而增加。
- 在轻微-中度改善中,仅医生报告疾病活动度的贡献显著高于MRC预期。
- 至少轻微改善的患者中,95%有肌肉相关指标改善,多数(84%)有患者报告结局改善。
- 轻微改善者中位有1项核心指标恶化,中度-重大改善者多数无核心指标恶化;医生评估的变化总体与MRC改善分类一致。
关键数值与推荐
- MRC分类:无改善37%、轻微改善24%、中度改善25%、重大改善14%(n=412)。
- 至少轻微改善者中肌肉相关指标改善占95%,患者报告结局改善占84%。
- 轻微改善者中位恶化核心指标数为1项。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The ACR-EULAR Myositis Response Criteria (MRC) were developed as a composite measure using absolute percentage change in six core set measures (CSMs). We aimed to further validate the MRC by assessing the contribution of each CSM, frequency of strength vs extramuscular activity improvement, representation of patient-reported outcome measures (PROM), and frequency of CSM worsening. METHODS: Data from adult dermatomyositis/polymyositis patients in the rituximab (n = 147), etanercept (n = 14), and abatacept (n = 19) trials, and consensus patient profiles (n = 232) were evaluated. The Total Improvement Score (TIS), number of improving vs worsening CSMs, frequency of improvement with and without muscle-related CSMs, and contribution of PROM were evaluated by MRC category. Regression analysis was performed to assess contribution of each CSM to the MRC. RESULTS: Of 412 adults with dermatomyositis/polymyositis, there were 37%, 24%, 25%, and 14% with no, minimal, moderate, and major MRC improvement, respectively. The number of improving CSMs and absolute percentage change in all CSMs increased by improvement category. In minimal-moderate improvement, only physician-reported disease activity contributed significantly more than expected by MRC. Of patients with at least minimal improvement, 95% had improvement in muscle-related measures and a majority (84%) had improvement in PROM. Patients with minimal improvement had worsening in a median of 1 CSM, and most patients with moderate-major improvement had no worsening CSMs. Physician assessment of change generally agreed with MRC improvement categories. CONCLUSION: The ACR-EULAR MRC performs consistently across multiple studies, further supporting its use as an efficacy end point in future myositis therapeutic trials.
引用
- Saygin D, Kim H, Douglas C, et al. Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles. Rheumatology (Oxford). 2023. PMID: 36929923. doi:10.1093/rheumatology/kead110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。